Account
Articles
08.09.2025
The JCA is here – are you generating the right e...

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu...

Read more
Articles
20.08.2025
Reassessing Clinically Meaningful Differences in A...

The recent Medicines and Healthcare products Regulatory Agency (MHRA) approval of the Alzheimer’s ...

Read more
Articles
11.08.2025
Why your PICO strategy matters to successful JCA 

The Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...

Read more
Articles
14.07.2025
Engaging Stakeholders: The Power of Patient and Cl...

Decisions regarding National Institute for Health and Care Excellence (NICE) appraisals are not made...

Read more
Articles
07.07.2025
NICE 2025 Update: How New Appraisal Reforms Impact...

The National Institute of Health and Care Excellence (NICE) has published several updates and releas...

Read more
Articles
30.06.2025
Avoiding pitfalls: Top 5 reasons NICE HST/STA subm...

Most pharmaceutical products hoping to launch in the UK will be assessed by NICE as a Single Technol...

Read more
Articles
25.06.2025
Mastering NICE submissions: The three pillars for ...

Securing a positive recommendation from the National Institute for Health and Care Excellence (NICE)...

Read more
Articles
16.06.2025
HST or STA? Navigating NICE’s Dual Pathways for ...

When bringing a new health technology to market in England, pharmaceutical and biotech companies mus...

Read more
Articles
02.06.2025
Joint Scientific Consultations: When, Why, and How...

The increasing complexity of bringing innovative therapies to market across various jurisdictions pr...

Read more
Articles
19.05.2025
Avoiding Common Pitfalls in HTA Scientific Advice:...

With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.